This Is Why Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) CEO Compensation Looks Appropriate [Yahoo! Finance]
Praxis Precision Medicines, Inc. (PRAX)
Company Research
Source: Yahoo! Finance
The total compensation is 50% less than the average for the industry Praxis Precision Medicines' three-year loss to shareholders was 84% while its EPS grew by 30% over the past three years Shareholders may be wondering what CEO Marcio De'Souza plans to do to improve the less than great performance at Praxis Precision Medicines, Inc. NASDAQ:PRAX ) recently. They will get a chance to exercise their voting power to influence the future direction of the company in the next AGM on 5th of June. It has been shown that setting appropriate executive remuneration incentivises the management to act in the interests of shareholders. In our opinion, CEO compensation does not look excessive and we discuss why. View our latest analysis for Praxis Precision Medicines How Does Total Compensation For Marcio De'Souza Compare With Other Companies In The Industry? According to our data, Praxis Precision Medicines, Inc. has a market capitalization of US$773m, and paid its CEO total annual compen
Show less
Read more
Impact Snapshot
Event Time:
PRAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRAX alerts
High impacting Praxis Precision Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
PRAX
News
- Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International CongressGlobeNewswire
- Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.MarketBeat
- Praxis Precision Medicines to Participate in Upcoming Investor ConferencesGlobeNewswire
- Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $143.00 price target on the stock, up previously from $134.00.MarketBeat
- Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentationsGlobeNewswire
PRAX
Earnings
- 8/13/24 - Beat
PRAX
Sec Filings
- 9/23/24 - Form SC
- 9/3/24 - Form 8-K
- 8/13/24 - Form 10-Q
- PRAX's page on the SEC website